Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Ecoza

(Oteseconazole with Flucytosine - antifungal therapy 4)

0

Indications

1

Total Trials

1

Active Trials

0

Competitors

3

FDA Applications

NDA/BLA/ANDA regulatory filings

Timeline

Expected Milestones

Q2 2032

PreclinicalRecruiting

HIV

NCT06666322

Clinical

Trials by Indication[1]

HIV1 trial

Platform Trial For Cryptococcal Meningitis

Recruiting·UUniversity of Minnesota·Preclinical·NCT06666322·2,000 enrolled

Regulatory

FDA Approval Timeline[3]

Dec 23, 1982

SPECTAZOLE

NDA NDA018751

Oct 24, 2013

ECOZA

NDA NDA205175

Apr 26, 2022

VIVJOA

NDA NDA215888

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Oteseconazole with Flucytosine - antifungal therapy 4. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oteseconazole with Flucytosine - antifungal therapy 4 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA215888). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Alvogen Korea company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Company: AAlvogen Korea

Related News